Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loxapine + midazolam
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral (loxapine), Intramuscular (loxapine), Inhalation (loxapine), Intravenous (midazolam), Intranasal (midazolam), Oral (midazolam)
01
Overview
This is a combination of two pharmaceutical agents: loxapine and midazolam. Loxapine is a typical antipsychotic primarily used in the treatment of schizophrenia and acute agitation. It acts mainly as a dopamine D2 receptor antagonist and also blocks serotonin 5-HT2 receptors, though its precise mechanism is not fully established[1][4][5]. Midazolam is a short-acting benzodiazepine with sedative, anxiolytic, muscle relaxant, anticonvulsant, hypnotic, and amnesic properties. It acts as a positive allosteric modulator at the GABA(A) receptor complex[3]. The combination may be used in clinical settings for rapid control of acute agitation or severe behavioral disturbances where both sedation and antipsychotic effects are desired[2][4]. The use together increases risk of CNS depression due to additive effects on sedation[7].
- Brand names
- Adasuve (loxapine)Xylac (loxapine)
- Other names
- LoxapinaLoxapinumOxilapine (for loxapine)
02
Targets
DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)BZD site (GABA-A receptor benzodiazepine site)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on loxapine + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loxapine + midazolam.